# Carlos H. Barrios

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carlos-h-barrios/

## Facts

| Field | Value |
| --- | --- |
| Citations | 66,291 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 89 |
| i10-index | 234 |
| Last Known Institution | Centro Brasileiro de Estudos em Dermatologia |
| OpenAlex ID | https://openalex.org/A5102881127 |
| ORCID iD | https://orcid.org/0000-0001-6021-667X |
| Works | 509 |

## Researcher papers

Showing 12 of 16.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/early-breast-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Centro Brasileiro de Estudos em Dermatologia](https://scholariq.org/institutions/centro-brasileiro-de-estudos-em-dermatologia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.